Google Secures Pentagon AI Deal for Classified Projects 
U.S. Warns Allies Over Alleged Chinese AI IP Theft Linked to DeepSeek 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Sun Pharma to Acquire Organon in $11.75 Billion Deal to Boost Global Women’s Health Portfolio 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
U.S. Budget Airlines Seek $2.5 Billion Government Aid Amid Rising Jet Fuel Costs 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips 
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
NEW YORK, April 13, 2017 -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical stage biopharmaceutical company focused on the development of innovative cancer therapies, today announced that it will host an operational update conference call with the investment community on Friday, April 28, 2017, at 8:30 a.m. Eastern Time.
The conference call will feature remarks by Dr. Lan Huang, Ph.D., Chairman and CEO, and Richard Brand, CFO. The dial-in numbers for the conference call are +1.877.451.6152 (U.S. Toll Free) or +1.201.389.0879 (International). Please ask the operator to join you into the BeyondSpring Call.
A live webcast of the conference call will be available online which can be accessed through the Investor Relations section of BeyondSpring’s website, http://ir.beyondspringpharma.com. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast.
For interested individuals unable to join the conference call, a replay of the call will be available through May 12, 2017, at +1.844.512.2921 (U.S. Toll Free) or +1.412.317.6671 (International). Participants must use the following code to access the replay of the call: 13659965. Also, a replay of the webcast will remain available on http://ir.beyondspringpharma.com for 30 days following the call.
The Company also plans to issue an operational update press release on Friday, April 28th before the U.S. markets open, which will include its financial results for the year ended December 31, 2016.
About BeyondSpring
BeyondSpring is a global clinical stage biopharmaceutical company developing innovative immuno-oncology cancer therapies with a robust pipeline from internal development and from collaboration with Fred Hutchinson Cancer Research Center and University of Washington. BeyondSpring is advancing its lead asset, Plinabulin, into a Phase 3 clinical trial as a direct anticancer agent in non-small cell lung cancer and a Phase 2/3 clinical trial in the prevention of chemotherapy-induced Neutropenia. BeyondSpring has a seasoned management team with many years of experience bringing drugs to market.
Investor Relations: Garth Russell / Allison Soss KCSA Strategic Communications P: +1-212-682-6300 [email protected] / [email protected] Media Relations: Caitlin Kasunich / Amy Singh KCSA Strategic Communications 212.896.1241 / 212.896.1207 [email protected] / [email protected]
